Like other biotechs without any revenue, its value proposition to shareholders is contingent on the success of its clinical trials. The company's drug, simufilam, recently completed its phase 2 clinical trials, and the company plans to start phase 3 before the end of 2021. On July 29, Cassava reported a packet of data showing that simufilam improved cognition, slowed the progression of Alzheimer's disease, and elicited positive changes in a smattering of biomarkers.
Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
As if to prove the point that what goes up, must come down, shares of Cassava Sciences (SAVA) took a real beating last week. One of 2021’s star performers, SAVA stock had been on an absolute tear this year, as investors took a shine to the Alzheimer’s disease (AD) focused company following the release of promising data for its prospective AD treatment simufilam. However, in two consecutive sessions, shares shed a combined 56% after the company presented results from an interim analysis for the d